Page 31 - Morphosys Expected News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys expected. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Expected Today - Breaking & Trending Today

MorphoSys AG: MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosisData presented during poster and oral sessions at the 63rd American ....

United States , Srdan Verstovsek , Development Officer , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Drug Administration , Morphosys Group , Md Anderson Cancer Center , Constellation Pharmaceuticals Inc , Janssen Research Development , Morphosys Us Inc , Exchange Commission , Constellation Pharmaceuticals , American Society , Hematology Annual Meeting , Malte Peters , Morphosys Chief Research , Cancer Center , Janssen Research , Janssen Biotech , Morphosy Annual Report ,

MorphoSys AG: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies- Results from the retrospective cohort analysis indicate significant ....

United States , Grzegorz Nowakowski , Peter Langmuir , Nuwan Kurukulasuriya , Practice Research Clinical Haematology , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Xencor Inc , Group Vice , Drug Administration , Global Head Of Medical Affairs , Janssen Research Development , Morphosys Us Inc , Exchange Commission , Meeting Of The Society Hematologic Oncology , European Medicines Agency , Hematologic Oncology , American Society , Hematology Annual Meeting , Mayo Clinic , Senior Vice President , Global Head , Medical Affairs , Group Vice President , Oncology Targeted Therapies , Diffuse Largeb Cell Lymphoma ,

MorphoSys AG: Corporate Calendar 2022

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022Dear Madam/Sir,Please note MorphoSys' financial reporting dates 2022 as follows:Publication of Interim Statement / ReportConference ....

Thomas Biegi , Julia Neugebauer , Myles Clouston , Jeanette Bressi , Janssen Biotech Inc , Drug Administration , Morphosys Group , Constellation Pharmaceuticals Inc , Janssen Research Development , Morphosys Us Inc , Us Communications , Exchange Commission , Corporate Calendar , Interim Statement , End Results , Quarter Interim Statement , Year Report , Janssen Research , Janssen Biotech , Constellation Pharmaceuticals , Morphosy Annual Report ,

MorphoSys AG: MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting

Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathyPLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4 ....

United States , Brad Rovin , Thomas Biegi , Julia Neugebauer , Myles Clouston , Jeanette Bressi , Janssen Biotech Inc , Ohio State University , Drug Administration , Morphosys Group , Constellation Pharmaceuticals Inc , Janssen Research Development , Morphosys Us Inc , Exchange Commission , Us Communications , Meeting Of The American Society Nephrology , American Society , Malte Peters , Chief Research , Development Officer , Membranous Nephropathy , I Mab Biopharma , Janssen Research , Janssen Biotech , Constellation Pharmaceuticals , Morphosy Annual Report ,

MorphoSys AG Announces Monjuvi Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to € ....

United States , United Kingdom , Thomas Biegi , Julia Neugebauer , Myles Clouston , Jeanette Bressi , Janssen Biotech Inc , Drug Administration , Morphosys Group , Constellation Pharmaceuticals Inc , Janssen Research Development , Morphosys Us Inc , Exchange Commission , Us Communications , Management Board , Janssen Research , Janssen Biotech , Constellation Pharmaceuticals , Morphosy Annual Report ,